<DOC>
	<DOCNO>NCT02596334</DOCNO>
	<brief_summary>Triple antiretroviral regimen greatly improve prognosis patient live HIV ( PLHIV ) . Patients virologically control good immune restoration life expectancy close equal people infect HIV . [ 1 ] However , condition `` lifetime '' maintenance undetectable plasma viral load ( pVL ) ( &lt; 50 cp/ml ) . On hand well establish age increase comorbidities among PLHIV burden co-medications . [ 2 ] This also consequence frequent drug-drug interaction . In context important decrease pill burden , side-effects drug-drug interaction , maintain undetectability . Currently , strong interest medical research validate lighten regimen ( i.e . bithérapies [ 3-7 ] monothérapies [ 8,9 ] , particularly maintenance strategy , primary objective reduce burden pill side effect . Several monotherapy trial use boosted protease inhibitor ( PI/r ) show high level viral suppression , even proportion always non-inferior maintain triple therapy . [ 8,9 ] Fortunately , virological failure occur monotherapy virologic suppression easily restore addition two NRTI . Patients likely maintain viral suppression reduce scheme high nadir ( &gt; 100 CD4 / mm3 ) , previous AIDS event sustain virologic suppression ( &gt; 12 month ) . Monotherapy option best reduces burden pill risk side effect drug-drug interaction . It must consider use powerful molecule harbor strong binding ligand order minimize risk select resistant mutant case virologic failure . To simple possible use , must single agent administer single dose day boost possible . The molecule must good tolerance . Finally , effective viral sanctuary molecule good ( sufficient ) diffusion ensure effective Cmin wild viral strain . Dolutegravir meet exigences . [ 10 ] In addition , team recently present result pilot study show switch successful combined antiretroviral regimen dolutegravir monotherapy maintain undetectable viral load ( &lt; 20 cp/ml ) median 7 month ( range 6.5-10 month ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy MONotherapy TiviCAY® Versus Triple Therapy HIV-1-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>HIV1infected patient previous AIDS event ( exclude heal tuberculosis ) ; Current antiretroviral treatment associate dolutegravir + abacavir + lamivudine least 1 month ; Nadir CD4 ≥ 100/mm3 ; Plasma RNA viral load &lt; 50 copies/ml least 12 month ; Plasma RNA viral load &lt; 20 40 copies/ml ( accord threshold method use local laboratory ) screen visit ; No document virologic failure know resistance integrase inhibitor , Patient provide write consent ; Patients followup possible ambulatory ; Patient age &gt; 18 year ; Covered health insurance Noncompliant patient Subject pregnant , lactating , childbearing potential without contraception ; Active opportunistic infection ( define AIDS ) ; Known hypersensibility abacavir lamivudine dolutegravir ; Patients harbor HLA B*5701 ; Major overweight ( BMI ≥ 40 ) ; Weight &lt; 40 kg ; Creatinine clearance &lt; 50ml/min ; Cirrhosis severe liver failure ( factor V &lt; 50 % ) ; Life Prognosis threaten within 6 month ; Circumstances may impair judgment understand information give patient ; Comedication carbamazepin , oxcarbamazepin , fosphenytoïn , phenobarbital , phenytoïn , primidon , St John 's wort dofetilid ; Malabsorption syndromes ; The follow laboratory criterion : Serum AST , ALT &gt; 5 x upper limit normal ( ULN ) Thrombocytopenia platelet count &lt; 50.000/ml Anemia hemoglobin &lt; 8g/dl Polynuclear neutrophil count &lt; 500/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV-1 infect patient</keyword>
	<keyword>monotherapy</keyword>
	<keyword>dolutegravir</keyword>
</DOC>